KRAS and neoplasm: The exclusion of NSCLCs with known driver mutations appears to be essential in this context: for example, a clinical trial involving HER2 tumor targeting demonstrated the advantage of this therapy only in patients with KRAS mutation-negative tumors, while patients with RAS activation had no clear benefit from the treatment [29].